Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.7% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 177,604 shares of the biopharmaceutical company’s stock after buying an additional 4,745 shares during the period. Assenagon Asset Management S.A.’s holdings in Regeneron Pharmaceuticals were worth $126,513,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in REGN. Rakuten Securities Inc. raised its stake in Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 19 shares during the last quarter. FSA Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at about $26,000. Fairfield Financial Advisors LTD purchased a new position in shares of Regeneron Pharmaceuticals in the third quarter worth about $37,000. Ashton Thomas Private Wealth LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth about $39,000. Finally, Truvestments Capital LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth about $39,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on REGN. Wolfe Research started coverage on shares of Regeneron Pharmaceuticals in a research report on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price target for the company. Truist Financial reduced their target price on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a report on Wednesday, January 8th. Piper Sandler decreased their target price on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Barclays cut their price target on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Finally, Royal Bank of Canada decreased their price objective on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a report on Friday, November 1st. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $1,032.57.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock opened at $690.87 on Wednesday. The firm’s 50-day moving average is $746.43 and its two-hundred day moving average is $956.18. Regeneron Pharmaceuticals, Inc. has a 12 month low of $666.25 and a 12 month high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The company has a market capitalization of $75.92 billion, a PE ratio of 17.10, a price-to-earnings-growth ratio of 2.19 and a beta of 0.10.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.